US Edition
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
- On May 14, 2025, Citius Pharmaceuticals, Inc. From Cranford, N.J. Announced its business update along with financial performance figures for the quarter ending March 31, 2025.
- The company completed Phase 3 trials for LYMPHIR and Mino-Lok last year, both meeting primary endpoints, and received FDA approval for LYMPHIR in August 2024.
- Citius Pharma focused on launching LYMPHIR through its 92%-owned subsidiary Citius Oncology, while engaging the FDA on next steps and securing financing including a recent registered direct offering.
- The company recorded a net loss of $11.5 million for the quarter, with R&D expenses of $3.8 million and general administrative expenses of $4.8 million, reflecting increased pre-launch costs.
- Citius Pharma will need additional capital beyond May 2025 to support operations and plans to continue funding Citius Oncology while exploring strategic partnerships and commercialization strategies.
35 Articles
35 Articles
Bennington Banner
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
CRANFORD, N.J., May 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal…
GCT Semiconductor Holding, Inc. Provides Business Update and Reports First Quarter 2025 Financial Results
5G chipset sampling to customers scheduled to begin at the end of May, following completion of fab, wafer processing and delivery of finalized 5G chipsets to GCT facility SAN JOSE, Calif.--(BUSINESS WIRE)--#4G--GCT Semiconductor Holding, Inc. (“GCT” o... L'articolo GCT Semiconductor Holding, Inc. Provides Business Update and Reports First Quarter 2025 Financial Results è un contenuto originale di 01net.
Release - Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - Channelchek
Research News and Market Data on UNCY May 14, 2025 7:15am EDT Download as PDF – Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025 – New data from patient surveys and patient-reported outcomes studies highlight adhere…
Coverage Details
Bias Distribution
- 64% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
